Freeline Therapeutics
Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
Total raised
€178M
€177,828,000
Funding rounds
2
Investors
4
distinct backers
Active since
2020-07
latest 2020-07
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood23
base rate 51% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
Exit likelihood20
base rate 12% (2+ rounds)
- ▲ €100M+ raised
- ▲ 11y since founding
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-07-05 | Series C | €71M | Eventide Asset Management,Novo Holdings,Wellington Management | View deal → |
| 2020-07-05 | Series C | €107M | Eventide Asset Management,Novo Holdings,Syncona Partners LLP,Wellington Management | View deal → |